Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:cyclobutanes
go back to main search page
Accession:CHEBI:156473 term browser browse the term
Definition:Cyclobutane and its derivatives formed by substitution.
Synonyms:xref_mesh: MESH:D003503


show annotations for term's descendants           Sort by:
 
cyclobutanes term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NR1I3 nuclear receptor subfamily 1 group I member 3 increases activity EXP Cyclobutanes results in increased activity of NR1I3 protein CTD PMID:28927721 NCBI chr 1:161,229,666...161,238,623
Ensembl chr 1:161,229,666...161,238,302
Ensembl chr 1:161,229,666...161,238,302
JBrowse link
carboplatin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 decreases expression EXP Carboplatin results in decreased expression of ABCB1 mRNA; Carboplatin results in decreased expression of ABCB1 protein CTD PMID:27692344 NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
Ensembl chr 7:87,503,017...87,713,323
JBrowse link
G ABCB4 ATP binding cassette subfamily B member 4 decreases expression ISO Carboplatin results in decreased expression of ABCB4 mRNA CTD PMID:18172885 NCBI chr 7:87,398,988...87,476,722
Ensembl chr 7:87,401,697...87,480,435
Ensembl chr 7:87,401,697...87,480,435
JBrowse link
G ABCC1 ATP binding cassette subfamily C member 1 decreases expression EXP Carboplatin results in decreased expression of ABCC1 mRNA; Carboplatin results in decreased expression of ABCC1 protein CTD PMID:27692344 NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074
Ensembl chr16:15,949,577...16,143,074
JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 decreases expression EXP Carboplatin results in decreased expression of ABCC2 mRNA; Carboplatin results in decreased expression of ABCC2 protein CTD PMID:27692344 NCBI chr10:99,782,602...99,853,741
Ensembl chr10:99,782,640...99,852,594
JBrowse link
G ABCG2 ATP binding cassette subfamily G member 2 (Junior blood group) decreases expression EXP Carboplatin results in decreased expression of ABCG2 mRNA; Carboplatin results in decreased expression of ABCG2 protein CTD PMID:27692344 NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
JBrowse link
G ACVR1C activin A receptor type 1C increases response to substance EXP ACVR1C results in increased susceptibility to Carboplatin CTD PMID:21224400 NCBI chr 2:157,526,767...157,628,864
Ensembl chr 2:157,526,767...157,628,864
JBrowse link
G AKR1B1 aldo-keto reductase family 1 member B increases expression ISO Carboplatin results in increased expression of AKR1B1 mRNA CTD PMID:18172885 NCBI chr 7:134,442,350...134,459,239
Ensembl chr 7:134,442,356...134,459,284
JBrowse link
G AKT1 AKT serine/threonine kinase 1 multiple interactions ISO Pravastatin inhibits the reaction [Carboplatin results in increased activity of and results in increased phosphorylation of AKT1 protein] CTD PMID:18483861 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
JBrowse link
G ALAS2 5'-aminolevulinate synthase 2 decreases expression ISO Carboplatin results in decreased expression of ALAS2 mRNA CTD PMID:21296123 NCBI chr  X:55,009,055...55,030,977
Ensembl chr  X:55,009,055...55,030,977
JBrowse link
G ALDH1A1 aldehyde dehydrogenase 1 family member A1 affects response to substance EXP ALDH1A1 protein affects the susceptibility to Carboplatin CTD PMID:18854779 NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442
JBrowse link
G ALDH3A1 aldehyde dehydrogenase 3 family member A1 affects response to substance EXP ALDH3A1 protein affects the susceptibility to Carboplatin CTD PMID:18854779 NCBI chr17:19,737,984...19,748,390
Ensembl chr17:19,737,984...19,748,943
JBrowse link
G ANXA4 annexin A4 decreases response to substance
affects localization
multiple interactions
EXP ANXA4 protein results in decreased susceptibility to Carboplatin
Carboplatin affects the localization of ANXA4 protein
ATP7A protein promotes the reaction [ANXA4 protein results in decreased susceptibility to Carboplatin]
CTD PMID:24150977 NCBI chr 2:69,643,808...69,827,112
Ensembl chr 2:69,644,425...69,827,112
JBrowse link
G ARFGEF1 ADP ribosylation factor guanine nucleotide exchange factor 1 increases response to substance EXP ARFGEF1 results in increased susceptibility to Carboplatin CTD PMID:21755009 NCBI chr 8:67,174,298...67,343,824
Ensembl chr 8:67,173,511...67,343,781
JBrowse link
G ATP1A1 ATPase Na+/K+ transporting subunit alpha 1 decreases expression ISO Carboplatin results in decreased expression of ATP1A1 mRNA CTD PMID:18172885 NCBI chr 1:116,372,986...116,410,259
Ensembl chr 1:116,372,668...116,410,261
JBrowse link
G ATP7A ATPase copper transporting alpha affects localization
multiple interactions
EXP Carboplatin affects the localization of ATP7A protein
[MIR495 mRNA results in decreased expression of ATP7A protein] which results in increased susceptibility to Carboplatin; ATP7A protein promotes the reaction [ANXA4 protein results in decreased susceptibility to Carboplatin]
CTD PMID:24038379 PMID:24150977 NCBI chr  X:77,910,693...78,050,395
Ensembl chr  X:77,910,656...78,050,395
JBrowse link
G ATP7B ATPase copper transporting beta multiple interactions EXP ATP7B protein binds to and results in increased metabolism of Carboplatin CTD PMID:23751120 NCBI chr13:51,932,669...52,012,130
Ensembl chr13:51,930,436...52,012,125
JBrowse link
G BAX BCL2 associated X, apoptosis regulator decreases expression
multiple interactions
EXP Carboplatin results in decreased expression of BAX mRNA
Carboplatin results in increased cleavage of and results in increased expression of BAX protein
CTD PMID:15131059 PMID:15576332 NCBI chr19:48,954,825...48,961,798
Ensembl chr19:48,954,815...48,961,798
JBrowse link
G BCL2 BCL2 apoptosis regulator decreases expression EXP Carboplatin results in decreased expression of BCL2 mRNA; Carboplatin results in decreased expression of BCL2 protein CTD PMID:9664115 PMID:15576332 PMID:15996812 PMID:17404015 NCBI chr18:63,123,346...63,320,280
Ensembl chr18:63,123,346...63,320,128
JBrowse link
G BCL2L1 BCL2 like 1 decreases expression
multiple interactions
ISO Carboplatin results in decreased expression of BCL2L1 protein
Acetylcysteine inhibits the reaction [Carboplatin results in decreased expression of BCL2L1 protein]
CTD PMID:18483861 NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
JBrowse link
G BCL2L12 BCL2 like 12 increases expression EXP Carboplatin results in increased expression of BCL2L12 mRNA CTD PMID:15576332 NCBI chr19:49,664,834...49,673,916
Ensembl chr19:49,665,142...49,673,916
JBrowse link
G BECN1 beclin 1 multiple interactions
decreases expression
EXP Carboplatin promotes the reaction [Chloroquine results in decreased expression of BECN1 protein]; Chloroquine promotes the reaction [Carboplatin results in decreased expression of BECN1 protein] CTD PMID:27692344 NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
JBrowse link
G BIRC2 baculoviral IAP repeat containing 2 decreases response to substance EXP BIRC2 protein results in decreased susceptibility to Carboplatin CTD PMID:10815900 NCBI chr11:102,347,214...102,378,670
Ensembl chr11:102,347,211...102,378,670
JBrowse link
G BLMH bleomycin hydrolase decreases expression ISO Carboplatin results in decreased expression of BLMH mRNA CTD PMID:18172885 NCBI chr17:30,248,203...30,291,944
Ensembl chr17:30,248,203...30,292,056
JBrowse link
G BRCA1 BRCA1 DNA repair associated decreases activity EXP Carboplatin results in decreased activity of BRCA1 protein CTD PMID:20878461 NCBI chr17:43,044,295...43,125,364
Ensembl chr17:43,044,295...43,170,245
JBrowse link
G CAMKK2 calcium/calmodulin dependent protein kinase kinase 2 affects response to substance EXP CAMKK2 protein affects the susceptibility to Carboplatin CTD PMID:28634229 NCBI chr12:121,237,692...121,297,819
Ensembl chr12:121,237,675...121,298,308
JBrowse link
G CANX calnexin decreases expression ISO Carboplatin results in decreased expression of CANX mRNA CTD PMID:18172885 NCBI chr 5:179,678,646...179,731,641
Ensembl chr 5:179,678,628...179,731,641
JBrowse link
G CASP2 caspase 2 decreases expression ISO Carboplatin results in decreased expression of CASP2 mRNA CTD PMID:18172885 NCBI chr 7:143,288,351...143,307,696
Ensembl chr 7:143,288,215...143,307,696
JBrowse link
G CASP3 caspase 3 multiple interactions
increases activity
increases expression
EXP
ISO
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Carboplatin results in increased cleavage of and results in increased activity of CASP3 protein]; Carboplatin results in increased cleavage of and results in increased activity of CASP3 protein; palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP3 protein]
Carboplatin results in increased expression of CASP3 protein
Acetylcysteine inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]
Carboplatin results in increased expression of CASP3 mRNA
CTD PMID:15576332 PMID:16275998 PMID:18483861 PMID:20368269 PMID:22302033 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CASP7 caspase 7 increases activity
multiple interactions
EXP Carboplatin results in increased activity of CASP7 protein
palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP7 protein]
CTD PMID:22302033 NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
JBrowse link
G CASP9 caspase 9 increases activity
decreases expression
multiple interactions
increases expression
EXP
ISO
Carboplatin results in increased activity of CASP9 protein
Carboplatin results in decreased expression of CASP9 mRNA
Acetylcysteine inhibits the reaction [Carboplatin results in increased expression of CASP9 protein]; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP9 protein]
CTD PMID:15576332 PMID:15996812 PMID:17404015 PMID:18483861 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
JBrowse link
G CAT catalase decreases activity
decreases expression
multiple interactions
ISO Carboplatin results in decreased activity of CAT protein
Carboplatin results in decreased expression of CAT protein
Carboplatin results in decreased expression of and results in decreased activity of CAT protein
CTD PMID:11124453 PMID:15109710 PMID:15225673 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CD274 CD274 molecule decreases expression EXP Carboplatin results in decreased expression of CD274; Carboplatin results in decreased expression of CD274 protein CTD PMID:21765211 PMID:27692344 NCBI chr 9:5,450,542...5,470,554
Ensembl chr 9:5,450,503...5,470,566
JBrowse link
G CD44 CD44 molecule (Indian blood group) decreases expression ISO Carboplatin results in decreased expression of CD44 mRNA CTD PMID:18172885 NCBI chr11:35,139,168...35,232,402
Ensembl chr11:35,138,882...35,232,402
Ensembl chr11:35,138,882...35,232,402
JBrowse link
G CDC25B cell division cycle 25B decreases expression ISO Carboplatin results in decreased expression of CDC25B mRNA CTD PMID:21296123 NCBI chr20:3,786,951...3,806,118
Ensembl chr20:3,786,772...3,806,121
JBrowse link
G CDC42 cell division cycle 42 decreases expression ISO Carboplatin results in decreased expression of CDC42 mRNA CTD PMID:18172885 NCBI chr 1:22,052,709...22,101,360
Ensembl chr 1:22,025,511...22,101,360
JBrowse link
G CDKN1A cyclin dependent kinase inhibitor 1A increases expression EXP
ISO
Carboplatin results in increased expression of CDKN1A protein
Carboplatin results in increased expression of CDKN1A mRNA
CTD PMID:9664115 PMID:18172885 NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,339
Ensembl chr 6:36,676,460...36,687,339
JBrowse link
G CITED2 Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2 increases expression ISO Carboplatin results in increased expression of CITED2 mRNA CTD PMID:18172885 NCBI chr 6:139,371,807...139,374,648
Ensembl chr 6:139,371,807...139,374,648
JBrowse link
G CLU clusterin decreases expression ISO Carboplatin results in decreased expression of CLU mRNA CTD PMID:18172885 NCBI chr 8:27,596,917...27,614,700
Ensembl chr 8:27,596,917...27,614,700
JBrowse link
G COPS5 COP9 signalosome subunit 5 increases response to substance EXP COPS5 results in increased susceptibility to Carboplatin CTD PMID:21755009 NCBI chr 8:67,043,079...67,062,133
Ensembl chr 8:67,043,079...67,083,783
JBrowse link
G CYCS cytochrome c, somatic multiple interactions ISO Acetylcysteine inhibits the reaction [Carboplatin results in increased expression of CYCS protein]; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CYCS protein] CTD PMID:18483861 NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
JBrowse link
G DCT dopachrome tautomerase decreases response to substance EXP DCT protein results in decreased susceptibility to Carboplatin CTD PMID:15897911 NCBI chr13:94,436,811...94,549,406
Ensembl chr13:94,436,811...94,479,682
JBrowse link
G DDIT3 DNA damage inducible transcript 3 increases expression ISO Carboplatin results in increased expression of DDIT3 mRNA CTD PMID:18172885 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DDX53 DEAD-box helicase 53 affects response to substance EXP DDX53 gene SNP affects the susceptibility to Carboplatin CTD PMID:26378035 NCBI chr  X:22,999,960...23,003,589
Ensembl chr  X:22,999,960...23,003,589
JBrowse link
G DPYD dihydropyrimidine dehydrogenase multiple interactions EXP PCNA mRNA affects the reaction [DPYD mRNA affects the susceptibility to Carboplatin] CTD PMID:16685392 NCBI chr 1:97,077,743...97,921,059
Ensembl chr 1:97,077,743...97,995,000
JBrowse link
G EIF2S1 eukaryotic translation initiation factor 2 subunit alpha affects phosphorylation EXP Carboplatin affects the phosphorylation of EIF2S1 protein CTD PMID:29053414 NCBI chr14:67,360,328...67,386,516
Ensembl chr14:67,360,151...67,386,516
Ensembl chr14:67,360,151...67,386,516
JBrowse link
G EPCAM epithelial cell adhesion molecule multiple interactions EXP [Paclitaxel co-treated with Carboplatin] results in increased expression of EPCAM protein CTD PMID:12695858 NCBI chr 2:47,369,311...47,387,020
Ensembl chr 2:47,345,158...47,387,601
JBrowse link
G EPO erythropoietin increases expression ISO Carboplatin results in increased expression of EPO protein CTD PMID:17891399 NCBI chr 7:100,720,468...100,723,700
Ensembl chr 7:100,720,468...100,723,700
JBrowse link
G ERBB2 erb-b2 receptor tyrosine kinase 2 multiple interactions EXP ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin] CTD PMID:16446318 NCBI chr17:39,688,094...39,728,660
Ensembl chr17:39,687,914...39,730,426
JBrowse link
G FAS Fas cell surface death receptor increases expression EXP Carboplatin results in increased expression of FAS mRNA CTD PMID:15576332 NCBI chr10:88,968,429...89,017,059
Ensembl chr10:88,990,531...89,017,059
JBrowse link
G FSHB follicle stimulating hormone subunit beta increases expression ISO Carboplatin results in increased expression of FSHB protein CTD PMID:8776818 NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,016...30,235,261
Ensembl chr11:30,231,016...30,235,261
JBrowse link
G GSR glutathione-disulfide reductase decreases activity ISO Carboplatin results in decreased activity of GSR protein CTD PMID:11124453 NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
JBrowse link
G GSTP1 glutathione S-transferase pi 1 affects response to substance EXP GSTP1 gene affects the susceptibility to Carboplatin CTD PMID:12360105 NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
Ensembl chr11:67,583,742...67,586,656
JBrowse link
G H2AX H2A.X variant histone increases expression
multiple interactions
EXP Carboplatin results in increased expression of H2AX protein
palbociclib inhibits the reaction [Carboplatin results in increased expression of H2AX protein]
CTD PMID:22302033 NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,854...119,095,467
JBrowse link
G HAX1 HCLS1 associated protein X-1 multiple interactions ISO Pravastatin inhibits the reaction [Carboplatin results in decreased expression of HAX1 protein] CTD PMID:18483861 NCBI chr 1:154,272,629...154,275,875
Ensembl chr 1:154,272,589...154,275,875
Ensembl chr 1:154,272,589...154,275,875
JBrowse link
G HBB hemoglobin subunit beta decreases expression ISO Carboplatin results in decreased expression of HBB mRNA CTD PMID:21296123 NCBI chr11:5,225,464...5,227,071
Ensembl chr11:5,225,464...5,229,395
JBrowse link
G HMOX1 heme oxygenase 1 multiple interactions
increases expression
decreases response to substance
decreases expression
ISO
EXP
HMOX1 protein inhibits the reaction [Carboplatin results in increased activity of NFATC4]
Carboplatin results in increased expression of HMOX1 mRNA
HMOX1 protein results in decreased susceptibility to Carboplatin
Carboplatin results in decreased expression of HMOX1 mRNA
CTD PMID:18172885 PMID:20368269 PMID:21198546 PMID:26260164 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207
Ensembl chr22:35,380,361...35,394,207
JBrowse link
G HSD17B4 hydroxysteroid 17-beta dehydrogenase 4 decreases expression ISO Carboplatin results in decreased expression of HSD17B4 mRNA CTD PMID:18172885 NCBI chr 5:119,452,497...119,542,332
Ensembl chr 5:119,452,473...119,637,199
JBrowse link
G HSPA1A heat shock protein family A (Hsp70) member 1A increases expression ISO Carboplatin results in increased expression of HSPA1A mRNA CTD PMID:18172885 NCBI chr 6:31,815,543...31,817,942
Ensembl chr 6:31,815,543...31,817,946
JBrowse link
G HSPA1B heat shock protein family A (Hsp70) member 1B increases expression ISO Carboplatin results in increased expression of HSPA1B mRNA CTD PMID:18172885 NCBI chr 6:31,827,738...31,830,254
Ensembl chr 6:31,827,738...31,830,254
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 decreases expression ISO Carboplatin results in decreased expression of HSPA5 mRNA CTD PMID:18172885 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
JBrowse link
G HSPB1 heat shock protein family B (small) member 1 increases expression ISO Carboplatin results in increased expression of HSPB1 mRNA CTD PMID:18172885 NCBI chr 7:76,302,673...76,304,292
Ensembl chr 7:76,302,673...76,304,295
JBrowse link
G IGF2R insulin like growth factor 2 receptor decreases expression ISO Carboplatin results in decreased expression of IGF2R mRNA CTD PMID:18172885 NCBI chr 6:159,969,082...160,111,504
Ensembl chr 6:159,969,082...160,113,507
Ensembl chr 6:159,969,082...160,113,507
JBrowse link
G IL6 interleukin 6 decreases response to substance EXP IL6 protein results in decreased susceptibility to Carboplatin CTD PMID:7834629 NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
JBrowse link
G IL6R interleukin 6 receptor decreases response to substance EXP IL6R protein results in decreased susceptibility to Carboplatin CTD PMID:7834629 NCBI chr 1:154,405,343...154,469,450
Ensembl chr 1:154,405,193...154,469,450
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit decreases expression ISO Carboplatin results in decreased expression of JUN mRNA CTD PMID:18172885 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
JBrowse link
G KLK3 kallikrein related peptidase 3 multiple interactions EXP [Paclitaxel co-treated with Carboplatin] results in decreased expression of KLK3 protein CTD PMID:16442593 NCBI chr19:50,854,915...50,860,764
Ensembl chr19:50,854,915...50,860,764
JBrowse link
G MAP3K1 mitogen-activated protein kinase kinase kinase 1 decreases expression ISO Carboplatin results in decreased expression of MAP3K1 mRNA CTD PMID:18172885 NCBI chr 5:56,815,543...56,896,152
Ensembl chr 5:56,815,549...56,896,152
JBrowse link
G MAP3K12 mitogen-activated protein kinase kinase kinase 12 decreases expression ISO Carboplatin results in decreased expression of MAP3K12 mRNA CTD PMID:18172885 NCBI chr12:53,479,669...53,501,205
Ensembl chr12:53,479,669...53,500,063
JBrowse link
G MAPK14 mitogen-activated protein kinase 14 decreases expression ISO Carboplatin results in decreased expression of MAPK14 mRNA CTD PMID:18172885 NCBI chr 6:36,027,711...36,122,964
Ensembl chr 6:36,027,677...36,111,236
JBrowse link
G MAPK6 mitogen-activated protein kinase 6 decreases expression ISO Carboplatin results in decreased expression of MAPK6 mRNA CTD PMID:18172885 NCBI chr15:52,019,219...52,067,375
Ensembl chr15:51,952,106...52,067,375
JBrowse link
G MGMT O-6-methylguanine-DNA methyltransferase decreases expression ISO Carboplatin results in decreased expression of MGMT mRNA CTD PMID:18172885 NCBI chr10:129,467,241...129,770,983
Ensembl chr10:129,467,190...129,770,983
JBrowse link
G MIR155 microRNA 155 multiple interactions EXP [Carboplatin co-treated with Chloroquine] results in increased expression of MIR155 mRNA CTD PMID:27692344 NCBI chr21:25,573,980...25,574,044
Ensembl chr21:25,573,980...25,574,044
JBrowse link
G MIR495 microRNA 495 multiple interactions EXP [MIR495 mRNA results in decreased expression of ATP7A protein] which results in increased susceptibility to Carboplatin CTD PMID:24038379 NCBI chr14:101,033,755...101,033,836
Ensembl chr14:101,033,755...101,033,836
JBrowse link
G MIR630 microRNA 630 decreases response to substance EXP MIR630 mRNA results in decreased susceptibility to Carboplatin CTD PMID:20145152 NCBI chr15:72,587,217...72,587,313
Ensembl chr15:72,587,217...72,587,313
JBrowse link
G MPO myeloperoxidase multiple interactions ISO [Carboplatin co-treated with Carnitine deficiency] results in increased expression of MPO protein CTD PMID:18852009 NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
JBrowse link
G MSH2 mutS homolog 2 decreases expression ISO Carboplatin results in decreased expression of MSH2 mRNA CTD PMID:18172885 NCBI chr 2:47,403,067...47,634,501
Ensembl chr 2:47,403,067...47,663,146
Ensembl chr 2:47,403,067...47,663,146
JBrowse link
G MT1A metallothionein 1A decreases expression ISO Carboplatin results in decreased expression of MT1A mRNA CTD PMID:18172885 NCBI chr16:56,638,666...56,640,087
Ensembl chr16:56,638,666...56,640,087
JBrowse link
G MYC MYC proto-oncogene, bHLH transcription factor increases response to substance EXP MYC protein results in increased susceptibility to Carboplatin CTD PMID:21324178 NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
JBrowse link
G NANOG Nanog homeobox increases expression EXP Carboplatin results in increased expression of NANOG mRNA CTD PMID:25605917 NCBI chr12:7,789,402...7,799,146
Ensembl chr12:7,787,794...7,799,146
JBrowse link
G NBAS NBAS subunit of NRZ tethering complex affects response to substance EXP NBAS intron polymorphism affects the susceptibility to Carboplatin CTD PMID:21844884 NCBI chr 2:14,998,067...15,561,344
Ensembl chr 2:15,166,914...15,561,334
JBrowse link
G NCKAP1 NCK associated protein 1 decreases expression ISO Carboplatin results in decreased expression of NCKAP1 mRNA CTD PMID:18172885 NCBI chr 2:182,909,115...183,038,457
Ensembl chr 2:182,909,115...183,038,858
JBrowse link
G NFATC4 nuclear factor of activated T cells 4 multiple interactions
increases activity
ISO HMOX1 protein inhibits the reaction [Carboplatin results in increased activity of NFATC4] CTD PMID:21198546 NCBI chr14:24,366,911...24,379,604
Ensembl chr14:24,365,673...24,379,604
JBrowse link
G NFKB1 nuclear factor kappa B subunit 1 multiple interactions
decreases expression
EXP
ISO
Carboplatin results in increased activity of [NFKB1 protein binds to NFKB1 protein]; Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]]
Carboplatin results in decreased expression of NFKB1 mRNA
CTD PMID:12675310 PMID:18172885 NCBI chr 4:102,501,266...102,617,302
Ensembl chr 4:102,501,331...102,617,302
JBrowse link
G NFKBIA NFKB inhibitor alpha decreases phosphorylation
multiple interactions
EXP Carboplatin results in decreased phosphorylation of NFKBIA protein
NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]]
CTD PMID:12675310 PMID:15120608 NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,511...35,404,749
Ensembl chr14:35,401,511...35,404,749
JBrowse link
G NODAL nodal growth differentiation factor increases response to substance EXP NODAL results in increased susceptibility to Carboplatin CTD PMID:21224400 NCBI chr10:70,431,936...70,447,951
Ensembl chr10:70,431,936...70,447,951
JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 increases expression ISO Carboplatin results in increased expression of NQO1 mRNA CTD PMID:18172885 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
JBrowse link
G NRAS NRAS proto-oncogene, GTPase decreases expression ISO Carboplatin results in decreased expression of NRAS mRNA CTD PMID:18172885 NCBI chr 1:114,704,469...114,716,771
Ensembl chr 1:114,704,469...114,716,771
JBrowse link
G OR4D6 olfactory receptor family 4 subfamily D member 6 affects response to substance EXP OR4D6 gene SNP affects the susceptibility to Carboplatin CTD PMID:26378035 NCBI chr11:59,456,961...59,457,905
Ensembl chr11:59,456,938...59,457,991
JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 increases cleavage EXP Carboplatin results in increased cleavage of PARP1 protein CTD PMID:15996812 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
JBrowse link
G PAWR pro-apoptotic WT1 regulator decreases expression ISO Carboplatin results in decreased expression of PAWR mRNA CTD PMID:18172885 NCBI chr12:79,584,879...79,691,097
Ensembl chr12:79,574,979...79,690,964
JBrowse link
G PCNA proliferating cell nuclear antigen multiple interactions
increases expression
EXP
ISO
PCNA mRNA affects the reaction [DPYD mRNA affects the susceptibility to Carboplatin]; PCNA mRNA affects the reaction [TYMS mRNA affects the susceptibility to Carboplatin]
Carboplatin results in increased expression of PCNA mRNA
CTD PMID:16685392 PMID:18172885 NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
JBrowse link
G PDCD1LG2 programmed cell death 1 ligand 2 decreases expression
multiple interactions
EXP
ISO
Carboplatin results in decreased expression of PDCD1LG2
STAT6 gene mutant form inhibits the reaction [Carboplatin results in decreased expression of PDCD1LG2]
CTD PMID:21765211 NCBI chr 9:5,510,438...5,571,282
Ensembl chr 9:5,510,531...5,571,282
JBrowse link
G PDIA4 protein disulfide isomerase family A member 4 decreases expression ISO Carboplatin results in decreased expression of PDIA4 mRNA CTD PMID:18172885 NCBI chr 7:149,003,051...149,028,505
Ensembl chr 7:149,003,062...149,028,662
JBrowse link
G PDIA6 protein disulfide isomerase family A member 6 decreases expression ISO Carboplatin results in decreased expression of PDIA6 mRNA CTD PMID:18172885 NCBI chr 2:10,783,391...10,837,712
Ensembl chr 2:10,783,391...10,837,977
JBrowse link
G PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 increases expression EXP Carboplatin results in increased expression of PMAIP1 protein CTD PMID:20802529 NCBI chr18:59,899,996...59,904,305
Ensembl chr18:59,899,948...59,904,306
Ensembl chr18:59,899,948...59,904,306
JBrowse link
G PSMB2 proteasome 20S subunit beta 2 increases expression ISO Carboplatin results in increased expression of PSMB2 mRNA CTD PMID:18172885 NCBI chr 1:35,599,541...35,641,526
Ensembl chr 1:35,599,541...35,641,526
JBrowse link
G PSMB4 proteasome 20S subunit beta 4 decreases expression ISO Carboplatin results in decreased expression of PSMB4 mRNA CTD PMID:18172885 NCBI chr 1:151,399,573...151,401,937
Ensembl chr 1:151,399,560...151,401,937
JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 decreases response to substance
multiple interactions
EXP PTGS2 protein results in decreased susceptibility to Carboplatin
wortmannin inhibits the reaction [PTGS2 protein results in decreased susceptibility to Carboplatin]
CTD PMID:18089846 NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,423
JBrowse link
G RAB10 RAB10, member RAS oncogene family decreases expression ISO Carboplatin results in decreased expression of RAB10 mRNA CTD PMID:18172885 NCBI chr 2:26,034,084...26,137,454
Ensembl chr 2:26,034,084...26,137,454
JBrowse link
G RBM17 RNA binding motif protein 17 decreases response to substance EXP RBM17 protein results in decreased susceptibility to Carboplatin CTD PMID:16061639 NCBI chr10:6,089,034...6,117,447
Ensembl chr10:6,089,034...6,117,457
JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit multiple interactions EXP Carboplatin results in decreased localization of and results in decreased activity of RELA protein; Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]] CTD PMID:12675310 PMID:15120608 NCBI chr11:65,653,601...65,662,946
Ensembl chr11:65,653,597...65,663,090
JBrowse link
G SIK1 salt inducible kinase 1 increases response to substance EXP SIK1 results in increased susceptibility to Carboplatin CTD PMID:21755009 NCBI chr21:43,414,483...43,427,131
Ensembl chr21:43,414,483...43,427,131
JBrowse link
G SLC31A1 solute carrier family 31 member 1 decreases response to substance
multiple interactions
increases import
increases uptake
increases response to substance
ISO
EXP
SLC31A1 gene mutant form results in decreased susceptibility to Carboplatin
[Penicillamine results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin; [tetrathiomolybdate results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin; [Trientine results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin
SLC31A1 protein results in increased import of Carboplatin
SLC31A1 protein results in increased uptake of Carboplatin
SLC31A1 protein results in increased susceptibility to Carboplatin
CTD PMID:15634647 PMID:16847145 PMID:19509135 PMID:22914438 PMID:23123662 NCBI chr 9:113,221,544...113,264,492
Ensembl chr 9:113,221,544...113,264,492
JBrowse link
G SLC31A2 solute carrier family 31 member 2 decreases uptake ISO SLC31A2 protein results in decreased uptake of Carboplatin CTD PMID:19509135 NCBI chr 9:113,150,976...113,164,140
Ensembl chr 9:113,150,976...113,164,140
JBrowse link
G SMO smoothened, frizzled class receptor increases expression EXP Carboplatin results in increased expression of SMO mRNA CTD PMID:25605917 NCBI chr 7:129,188,633...129,213,548
Ensembl chr 7:129,188,633...129,213,545
JBrowse link
G SOD1 superoxide dismutase 1 multiple interactions
decreases expression
ISO Carboplatin results in decreased expression of and results in decreased activity of SOD1 protein
Carboplatin results in decreased expression of SOD1 protein
CTD PMID:15109710 PMID:15225673 NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,622...31,668,931
Ensembl chr21:31,659,622...31,668,931
JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions
decreases expression
ISO Carboplatin results in increased expression of and results in increased activity of SOD2 protein
Carboplatin results in decreased expression of SOD2 protein
CTD PMID:15109710 PMID:15225673 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
JBrowse link
G SOX2 SRY-box transcription factor 2 increases expression EXP Carboplatin results in increased expression of SOX2 mRNA CTD PMID:25605917 NCBI chr 3:181,711,925...181,714,436
Ensembl chr 3:181,711,925...181,714,436
JBrowse link
G STAT6 signal transducer and activator of transcription 6 multiple interactions ISO STAT6 gene mutant form inhibits the reaction [Carboplatin results in decreased expression of PDCD1LG2] CTD PMID:21765211 NCBI chr12:57,095,408...57,111,413
Ensembl chr12:57,095,408...57,132,139
JBrowse link
G STK39 serine/threonine kinase 39 decreases expression ISO Carboplatin results in decreased expression of STK39 mRNA CTD PMID:18172885 NCBI chr 2:167,954,020...168,247,595
Ensembl chr 2:167,954,020...168,247,595
JBrowse link
G STX2 syntaxin 2 increases response to substance EXP STX2 protein results in increased susceptibility to Carboplatin CTD PMID:24039787 NCBI chr12:130,789,600...130,839,274
Ensembl chr12:130,789,600...130,839,266
JBrowse link
G TFAP2A transcription factor AP-2 alpha increases response to substance EXP TFAP2A protein results in increased susceptibility to Carboplatin CTD PMID:16204029 NCBI chr 6:10,396,677...10,419,897
Ensembl chr 6:10,393,186...10,419,659
JBrowse link
G TNF tumor necrosis factor multiple interactions ISO [Carboplatin co-treated with Carnitine deficiency] results in increased expression of TNF protein CTD PMID:18852009 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
JBrowse link
G TNFRSF10B TNF receptor superfamily member 10b multiple interactions EXP [Carboplatin co-treated with Chloroquine] results in increased expression of TNFRSF10B protein CTD PMID:27692344 NCBI chr 8:23,020,133...23,069,031
Ensembl chr 8:23,020,133...23,069,031
JBrowse link
G TOP2A DNA topoisomerase II alpha multiple interactions EXP TOP2A results in decreased susceptibility to [Carboplatin co-treated with Etoposide co-treated with Ifosfamide] CTD PMID:11325482 NCBI chr17:40,388,525...40,417,902
Ensembl chr17:40,388,525...40,417,896
JBrowse link
G TP53 tumor protein p53 increases expression EXP Carboplatin results in increased expression of TP53 protein CTD PMID:9664115 PMID:15131059 NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
Ensembl chr17:7,661,779...7,687,538
JBrowse link
G TYMS thymidylate synthetase multiple interactions EXP PCNA mRNA affects the reaction [TYMS mRNA affects the susceptibility to Carboplatin] CTD PMID:16685392 NCBI chr18:657,653...673,578
Ensembl chr18:657,653...673,578
JBrowse link
G UGT1A6 UDP glucuronosyltransferase family 1 member A6 decreases expression ISO Carboplatin results in decreased expression of UGT1A6 mRNA CTD PMID:18172885 NCBI chr 2:233,691,670...233,773,300
Ensembl chr 2:233,691,607...233,773,300
JBrowse link
G VIM vimentin decreases expression ISO Carboplatin results in decreased expression of VIM mRNA CTD PMID:18172885 NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
JBrowse link
G XDH xanthine dehydrogenase affects activity ISO Carboplatin affects the activity of XDH protein CTD PMID:15225673 NCBI chr 2:31,334,320...31,414,777
Ensembl chr 2:31,334,321...31,414,742
JBrowse link
G XPC XPC complex subunit, DNA damage recognition and repair factor decreases response to substance ISO XPC results in decreased susceptibility to Carboplatin CTD PMID:19372135 NCBI chr 3:14,145,145...14,178,601
Ensembl chr 3:14,145,147...14,178,783
Ensembl chr 3:14,145,147...14,178,783
JBrowse link
G ZFP36L1 ZFP36 ring finger protein like 1 decreases expression ISO Carboplatin results in decreased expression of ZFP36L1 mRNA CTD PMID:18172885 NCBI chr14:68,787,655...68,796,243
Ensembl chr14:68,787,660...68,796,253
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 24372
    chemical entity 24340
      group 24224
        polyatomic entity 24224
          molecule 23800
            cyclic compound 23068
              organic cyclic compound 23068
                carbocyclic compound 21602
                  cyclobutanes 123
                    1-AMINOCYCLOBUTANECARBOXLIC ACID 0
                    3-ETHYLAMINO-4-METHYLAMINO-CYCLOBUTANE-1,2-DIONE 0
                    3-[8-amino-1-(2-phenyl-7-quinolinyl)-3-imidazo[1,5-a]pyrazinyl]-1-methyl-1-cyclobutanol 0
                    N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3R,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3R,4aS,9aR)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3R,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aR,9aS)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(2R,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]cyclobutanecarboxamide 0
                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide 0
                    N-[(2R,3S)-1-((2S)-2-\{[(cyclopentylamino)carbonyl]amino\}-3-methylbutanoyl)-2-(1-formylcyclobutan-1-yl)pyrrolidin-3-yl]cyclopropanecarboxamide 0
                    N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide 0
                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide 0
                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide 0
                    N-[(2S,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]cyclobutanecarboxamide 0
                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide 0
                    N-[(2S,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]cyclobutanecarboxamide 0
                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide 0
                    N-[(2S,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]cyclobutanecarboxamide 0
                    N-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                    N-[(5S,6R,9R)-8-(cyclobutanecarbonyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-1,2-oxazole-3-carboxamide 0
                    N-[(5S,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                    N-[(5S,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                    N-[(5S,6S,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                    N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(phenylmethyl)sulfonylamino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[(phenylmethyl)sulfonylamino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                    Pipercyclobutanamide A(rel) 0
                    cis-1,2-Diphenylcyclobutane 0
                    cyclobutane + 0
                    cyclobutanecarboxylic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester 0
                    cyclobutanedicarboxylate + 122
                    cyclobutanedicarboxylic acid + 0
                    cyclobutrifluram 0
                    octafluorocyclobutane 0
                    trans-1,2-Diphenylcyclobutane 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 24372
    subatomic particle 24329
      composite particle 24329
        hadron 24329
          baryon 24329
            nucleon 24329
              atomic nucleus 24329
                atom 24329
                  main group element atom 24177
                    p-block element atom 24177
                      p-block molecular entity 24170
                        carbon group molecular entity 23954
                          organic molecular entity 23912
                            organic molecule 23792
                              organic cyclic compound 23068
                                carbocyclic compound 21602
                                  cyclobutanes 123
                                    1-AMINOCYCLOBUTANECARBOXLIC ACID 0
                                    3-ETHYLAMINO-4-METHYLAMINO-CYCLOBUTANE-1,2-DIONE 0
                                    3-[8-amino-1-(2-phenyl-7-quinolinyl)-3-imidazo[1,5-a]pyrazinyl]-1-methyl-1-cyclobutanol 0
                                    N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3R,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3R,4aS,9aR)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3R,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aR,9aS)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(2R,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]cyclobutanecarboxamide 0
                                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide 0
                                    N-[(2R,3S)-1-((2S)-2-\{[(cyclopentylamino)carbonyl]amino\}-3-methylbutanoyl)-2-(1-formylcyclobutan-1-yl)pyrrolidin-3-yl]cyclopropanecarboxamide 0
                                    N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide 0
                                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide 0
                                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide 0
                                    N-[(2S,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]cyclobutanecarboxamide 0
                                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide 0
                                    N-[(2S,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]cyclobutanecarboxamide 0
                                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide 0
                                    N-[(2S,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]cyclobutanecarboxamide 0
                                    N-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                                    N-[(5S,6R,9R)-8-(cyclobutanecarbonyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-1,2-oxazole-3-carboxamide 0
                                    N-[(5S,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                                    N-[(5S,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                                    N-[(5S,6S,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                                    N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(phenylmethyl)sulfonylamino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                                    N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                                    N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                                    N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[(phenylmethyl)sulfonylamino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                                    Pipercyclobutanamide A(rel) 0
                                    cis-1,2-Diphenylcyclobutane 0
                                    cyclobutane + 0
                                    cyclobutanecarboxylic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester 0
                                    cyclobutanedicarboxylate + 122
                                    cyclobutanedicarboxylic acid + 0
                                    cyclobutrifluram 0
                                    octafluorocyclobutane 0
                                    trans-1,2-Diphenylcyclobutane 0
paths to the root